Sees FY26 sales $10.3B-$10.7B; Adjusted EBITDA includes synergy benefits of $50M-$75M, equating to a run rate of greater than $100M by the end of year one; Equity income from our China JV $65M-$75M; adjusted free cash flow $235M-$325M; Capital expenditures 4.5%-5% of sales; restructuring cash payments $110M-$150M; and Synergy implementation cash payments of $100M-$125M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCH: